Intervacc AB (publ) (STO:IVACC)

Market Cap	408.29M +16.1%
Revenue (ttm)	19.07M +30.3%
Net Income	-89.37M
EPS	-0.26
Shares Out	340.81M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	231,336
Average Volume	593,237
Open	1.200
Previous Close	1.198
Day's Range	1.150 - 1.230
52-Week Range	0.572 - 1.462
Beta	0.14
RSI	56.00
Earnings Date	Aug 20, 2026

About Intervacc AB

Intervacc AB (publ), a biotechnology company, engages in the research and development of vaccines for bacterial infections in animal health care. The company devlops vaccines for horses, piglets, and dairy cows. It offers Strangvac, a vaccine for equine strangles. The company also markets and sells veterinary medicines; and provides diagnostic services in veterinary bacteriology for veterinary clinics and stud farms. In addition, it is developing vaccines against streptococcus suis and staphylococcus aureus-infections. It serves customers in No...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1983
• Employees: 16
• Stock Exchange: Nasdaq Stockholm
• Ticker Symbol: IVACC

Financial Performance

In 2025, Intervacc AB's revenue was 20.09 million, an increase of 70.42% compared to the previous year's 11.79 million. Losses were -80.82 million, 7.02% more than in 2024.